Patient-Specific Dose-Finding Based On Bivariate Outcomes and Covariates
View Presentation *Peter F Thall, M.D. Anderson Cancer Center Keywords: Bayesian design, Individualized treatment, Phase I/II clinical trial A Bayesian method for individualized dose-finding based on efficacy and toxicity is presented. Dose-covariate interactions are included in the marginal outcome probabilities. Implementation requires an informative prior on covariate main effects. Elicited covariate-specific limits on the probabilities of efficacy and toxicity are used to construct bounding functions to determine the acceptability of each dose for each possible covariate vector. Each patient's dose is chosen to optimize the efficacy-toxicity trade-off for his/her covariates, based on elicited target outcome probability pairs. Because the selected doses are covariate-specific and the method is sequentially outcome-adaptive, different patients may receive different doses at the same point in the trial, and patient eligibility may change during the trial. The method is illustrated by a trial in acute leukemia.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC